NDA 208558 · Astrazeneca
Lynparza
Olaparib · Oral · Poly(ADP-Ribose) Polymerase Inhibitor
Priority reviewOrphanLast checked: Nov 20, 2026Latest source record: Jul 10, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2017
Aug 17, 2017
Approved uses
15
Original approval plus efficacy supplements
Registered trials
455
49 Phase 3, 83 recruiting
FAERS reports
21,443
19,511 serious, 6,079 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 10, 2025.
Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: Ovarian cancer • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA -mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.1 , 2.1 ) • in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either: • a deleterious or suspected deleterious BRCA mutation, and/or • genomic instability. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.2 , 2.1 ) • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.3 , 2.1 ) Breast cancer • for the adjuvant treatment of adult patients with deleterious or suspected deleterious g BRCA m human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.4 , 2.1 ) • for the treatment of adult patients with...
Mechanism: Olaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3. PARP enzymes are involved in normal cellular functions, such as DNA transcription and DNA repair. Olaparib has been shown to inhibit growth of select tumor cell lines in vitro and decrease tumor growth in mouse xenograft models of human cancer, both as monotherapy or following platinum-based chemotherapy. Increased cytotoxicity and anti-tumor activity following treatment with olaparib were noted in cell lines and mouse tumor models with deficiencies in BRCA1/2 , ATM , or other genes...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 6, 2023 Supplement 28 · Efficacy OrphanLetterLabel
- May 31, 2023 Supplement 25 · Efficacy · priority review LabelLetterReview
- Aug 26, 2022 Supplement 26 · Efficacy · priority review OrphanLetterLabel
- Mar 11, 2022 Supplement 23 · Efficacy · priority review LabelLetter
- Jan 31, 2022 Supplement 21 · Efficacy OrphanLetterLabel
- Mar 11, 2021 Supplement 19 · Efficacy OrphanLetterLabel
- Dec 7, 2020 Supplement 16 · Efficacy · priority review LetterLabel
- May 19, 2020 Supplement 14 · Efficacy · priority review LabelLetter
- May 8, 2020 Supplement 13 · Efficacy · priority review OrphanLabelLetter
- Dec 27, 2019 Supplement 10 · Efficacy · priority review OrphanLetterLabel
- Jul 1, 2019 Supplement 9 · Efficacy LetterLabel
- Dec 19, 2018 Supplement 6 · Efficacy · priority review OrphanLabelLetter
- Sep 26, 2018 Supplement 5 · Efficacy LabelLetter
- Jan 12, 2018 Supplement 1 · Efficacy · priority review LabelLetter
- Aug 17, 2017 Original approval · Type 3 - New Dosage Form · priority review OrphanLabelLetterReview
2 products under this application
- LYNPARZA · OLAPARIB 150MG · TABLET, ORAL · Prescription
- LYNPARZA · OLAPARIB 100MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Olaparib" as an intervention, any sponsor and status, largest first.
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerPivotal-lookingRecruiting
QuantumLeap Healthcare CollaborativeAcademic, hospital or other
NCT01042379 · 5,000 participants (planned) · Start Mar 1, 2010 · Primary completion Dec 2030
Drug: Standard Therapy; AMG 386 with or without Trastuzumab and 44 more · For: Breast Neoplasms; Breast Cancer; Breast Tumors and 8 more
Sites: Birmingham, Alabama; Scottsdale, Arizona; Tucson, Arizona · 42 sites in all
American Society of Clinical OncologyAcademic, hospital or other
NCT02693535 · 4,200 participants (planned) · Start Mar 14, 2016 · Primary completion Dec 31, 2027
Drug: Sunitinib (CLOSED TO ENROLLMENT); Trastuzumab and Pertuzumab (CLOSED TO ENROLLMENT) and 10 more · For: Lymphoma, Non-Hodgkin; Multiple Myeloma; Advanced Solid Tumors
Sites: Birmingham, Alabama; Phoenix, Arizona; Auburn, California · 181 sites in all
- Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT03486873 · 3,500 participants (planned) · Start Aug 21, 2018 · Primary completion Aug 4, 2043
Drug: Pembrolizumab; Standard of Care (SOC) and 5 more · For: Solid Tumors; Hematologic Malignancies
Sites: Tucson, Arizona; Bakersfield, California; Fresno, California · 782 sites in all
Oslo University HospitalAcademic, hospital or other
NCT04817956 · 3,000 participants (planned) · Start Apr 1, 2021 · Primary completion Mar 30, 2040
Drug: Atezolizumab · For: Cancer Metastatic
Sites: Ålesund, Norway; Bergen, Norway; Bodø, Norway · 17 sites in all
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialPivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT05564377 · 2,900 participants (planned) · Start Apr 7, 2023 · Primary completion Jul 1, 2030
Drug: Alpelisib; Binimetinib and 13 more · For: Advanced Malignant Solid Neoplasm; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8 and 12 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 484 sites in all
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06966700 · 2,400 participants (planned) · Start Jun 30, 2025 · Primary completion Mar 23, 2033
Drug: Sacituzumab tirumotecan; Pembrolizumab and 8 more · For: Breast Neoplasms; Triple Negative Breast Neoplasms; HR Low-Positive/HER2-Negative Breast Neoplasms
Sites: Gilbert, Arizona; Phoenix, Arizona; Tucson, Arizona · 338 sites in all
- A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast CancerPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT06112379 · 1,902 participants · Start Nov 14, 2023 · Primary completion Nov 20, 2028
Drug: Dato-DXd; Durvalumab and 8 more · For: Breast Cancer
Sites: Daphne, Alabama; Prescott, Arizona; Jonesboro, Arkansas · 283 sites in all
- Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast CancerPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT02032823 · 1,837 participants · Start Apr 22, 2014 · Primary completion Mar 27, 2020
Drug: Olaparib; Placebo · For: Breast Cancer
Sites: Anchorage, Alabama; Anchorage, Alaska; Gilbert, Arizona · 698 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death4,833
- malignant neoplasm progression2,129
- nausea1,903
- fatigue1,836
- anaemia1,670
- off label use971
- vomiting761
- neuropathy peripheral709
- drug ineffective689
- asthenia650
- diarrhoea638
- decreased appetite565
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2010 | 1 |
| 2012 | 6 |
| 2013 | 1 |
| 2014 | 6 |
| 2015 | 372 |
| 2016 | 506 |
| 2017 | 649 |
| 2018 | 851 |
| 2019 | 1,426 |
| 2020 | 2,047 |
| 2021 | 2,215 |
| 2022 | 2,367 |
| 2023 | 2,863 |
| 2024 | 3,375 |
| 2025 | 2,747 |
| 2026 | 2,011 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Lynparza (Olaparib)
2024 spending
$594M
Beneficiaries
7,016
41,444 claims
Per beneficiary
$84,654
$136.25 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $358,856,238 |
| 2021 | $426,649,225 |
| 2022 | $460,720,287 |
| 2023 | $487,431,793 |
| 2024 | $593,929,898 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial.
Westin SN, Moore K, Chon HS, et al. · J Clin Oncol 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
- Olaparib for Metastatic Castration-Resistant Prostate Cancer.
de Bono J, Mateo J, Fizazi K, et al. · N Engl J Med 2020 · Clinical Trial, Phase III, Multicenter Study
- Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial.
DiSilvestro P, Banerjee S, Colombo N, et al. · J Clin Oncol 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.
Tutt ANJ, Garber JE, Kaufman B, et al. · N Engl J Med 2021 · Clinical Trial, Phase III, Multicenter Study
- Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
Ray-Coquard I, Pautier P, Pignata S, et al. · N Engl J Med 2019 · Clinical Trial, Phase III, Multicenter Study
- Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance.
Wu W, Klockow JL, Zhang M, et al. · Pharmacol Res 2021 · Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
Sponsor: AstraZeneca
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.